Metrics Income Opportunities Trust (ASX:MOT) Declares Dividend
Metrics Income Opportunities Trust announces a dividend of AUD 0.0132 per ordinary unit, payable on 9 January 2025.
Category: Healthcare
Mayfield Childcare Limited (ASX:MFD) Enters Trading Halt
Mayfield Childcare Limited (ASX:MFD) has requested a trading halt pending an announcement regarding a corporate transaction.
Rhythm Biosciences Ltd (ASX: RHY) Acquires Genetype Business
Rhythm Biosciences (ASX: RHY) has acquired Genetype assets, enhancing its oncology portfolio and positioning for immediate revenue growth.
Ecofibre Limited (ASX:EOF) Secures New Loan Facilities
Ecofibre Limited (ASX:EOF) announces new loan facilities to support financial stability and operational efficiency.
Mach7 Technologies Limited (ASX:M7T) Signs New Contracts Worth A$4.6M
Mach7 Technologies Limited (ASX:M7T) announces the signing of A$4.6M in new contracts to enhance its PACS solutions and future revenue growth.
Imricor Medical Systems, Inc. (ASX: IMR) Submits NorthStar for CE Mark Approval
Imricor submits NorthStar for CE Mark approval and accelerates FDA submission, anticipating major advancements in cardiac procedures.
Acrux Limited (ASX:ACR) Raises $1.34 Million from Share Purchase Plan
Acrux Limited (ASX:ACR) raises $1.34 million through its Share Purchase Plan to advance its pharmaceutical development pipeline.
Lumos Diagnostics (ASX:LDX) Commences FebriDx CLIA Waiver Study
Lumos Diagnostics announces the launch of the FebriDx CLIA Waiver study, aimed at improving antibiotic use with substantial support from BARDA.
Epsilon Healthcare Limited (ASX:EPN) Update on Growth and Strategy
Epsilon Healthcare Limited (ASX:EPN) outlines its ambitious targets and operational capabilities, aiming for $14M revenue growth.
Mesoblast Limited (ASX:MSB) Achieves FDA Approval for RYONCIL
Mesoblast Limited announces FDA approval of RYONCIL, the first MSC therapy for children with steroid-refractory acute graft versus host disease.